Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib and Venetoclax in R/R CLL, SLL, or NHL
NCT02640833Phase 1Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Jul 2016
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of duvelisib and venetoclax in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), sponsored by AbbVie Inc. Primary endpoints: Number of participants with adverse events at 2 years, Maximum observed plasma concentration of duvelisib and 7 more. Planned start Jul 2016; status: withdrawn.
02
Drugs
duvelisibvenetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02640833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02640833.